Rapid manufacturing of non-activated potent CAR T cells
Menée à l'aide de lignées cellulaires, de modèles murins et d'échantillons sanguins d'origine humaine, cette étude présente une approche méthodologique pour générer rapidement, sans phase d'activation ou d'expansion, des lymphocytes CAR-T efficaces contre les cellules leucémiques
Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell haematologic malignancies. The manufacturing of these T cells typically involves their activation, followed by viral transduction and expansion ex vivo for at least 6 days. However, the activation and expansion of CAR T cells leads to their progressive differentiation and the associated loss of anti-leukaemic activity. Here we show that functional CAR T cells can be generated within 24 hours from T cells derived from peripheral blood without the need for T-cell activation or ex vivo expansion, and that the efficiency of viral transduction in this process is substantially influenced by the formulation of the medium and the surface area-to-volume ratio of the culture vessel. In mouse xenograft models of human leukaemias, the rapidly generated non-activated CAR T cells exhibited higher anti-leukaemic in vivo activity per cell than the corresponding activated CAR T cells produced using the standard protocol. The rapid manufacturing of CAR T cells may reduce production costs and broaden their applicability.
Nature Biomedical Engineering , article en libre accès, 2022